Wellington Management Group LLP boosted its position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 0.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 7,785,614 shares of the company's stock after purchasing an additional 15,843 shares during the period. Wellington Management Group LLP owned 13.58% of Structure Therapeutics worth $211,146,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. ANTIPODES PARTNERS Ltd raised its stake in shares of Structure Therapeutics by 115.0% during the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock worth $28,000 after purchasing an additional 553 shares in the last quarter. GAMMA Investing LLC raised its position in Structure Therapeutics by 4,155.6% during the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company's stock valued at $31,000 after acquiring an additional 1,122 shares in the last quarter. FNY Investment Advisers LLC bought a new position in Structure Therapeutics during the fourth quarter valued at approximately $40,000. Assetmark Inc. lifted its stake in Structure Therapeutics by 72.3% in the fourth quarter. Assetmark Inc. now owns 2,271 shares of the company's stock valued at $62,000 after acquiring an additional 953 shares during the last quarter. Finally, Jones Financial Companies Lllp increased its stake in shares of Structure Therapeutics by 29.8% during the 4th quarter. Jones Financial Companies Lllp now owns 4,228 shares of the company's stock worth $115,000 after purchasing an additional 971 shares during the last quarter. Hedge funds and other institutional investors own 91.78% of the company's stock.
Structure Therapeutics Price Performance
Shares of NASDAQ GPCR traded down $0.81 during trading hours on Monday, hitting $14.31. 976,864 shares of the company's stock were exchanged, compared to its average volume of 862,442. The company's 50-day moving average price is $22.75 and its 200-day moving average price is $30.17. Structure Therapeutics Inc. has a 1-year low of $13.73 and a 1-year high of $62.74. The stock has a market capitalization of $820.58 million, a price-to-earnings ratio of -19.34 and a beta of -1.35.
Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.01. On average, research analysts expect that Structure Therapeutics Inc. will post -0.82 earnings per share for the current year.
Analyst Ratings Changes
A number of research analysts have recently weighed in on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 price objective on shares of Structure Therapeutics in a research note on Thursday, December 19th. William Blair started coverage on Structure Therapeutics in a research report on Friday, February 28th. They issued an "outperform" rating for the company. Stifel Nicolaus started coverage on Structure Therapeutics in a research note on Wednesday, January 8th. They set a "buy" rating and a $50.00 price target for the company. Finally, JMP Securities reissued a "market outperform" rating and issued a $91.00 price objective on shares of Structure Therapeutics in a research note on Wednesday, December 18th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of "Buy" and an average price target of $81.29.
Check Out Our Latest Analysis on GPCR
About Structure Therapeutics
(
Free Report)
Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.
Featured Articles
Before you consider Structure Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Structure Therapeutics wasn't on the list.
While Structure Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
